From: Rapid and large-scale implementation of HCV treatment advances in France, 2007–2015
2014 | 2015 | |||||||
---|---|---|---|---|---|---|---|---|
Men | Women | Total | Men | Women | Total | |||
% | % | n | % | % | % | n | % | |
Total | 65.9 | 34.1 | 8702 | 100 | 64.4 | 35.6 | 14,650 | 100 |
Age group (years)a | ||||||||
< 30 | 0.3 | 0.3 | 30 | 0.3 | 0.8 | 0.7 | 112 | 0.8 |
30–39 | 2.6 | 1.3 | 184 | 2.1 | 4.3 | 2.1 | 519 | 3.5 |
40–49 | 20.6 | 9.4 | 1461 | 16.8 | 20.5 | 9.6 | 2441 | 16.7 |
50–59 | 50.1 | 30.5 | 3776 | 43.4 | 48.2 | 31.8 | 6204 | 42.4 |
60–69 | 18.6 | 31.0 | 1985 | 22.8 | 17.6 | 27.1 | 3068 | 20.9 |
70–79 | 6.3 | 22.1 | 1015 | 11.7 | 6.5 | 21.2 | 1716 | 11.7 |
80 and over | 1.5 | 5.4 | 249 | 2.9 | 2.1 | 7.5 | 585 | 4.0 |
Complementary Universal Health insurance (CMUC)a | ||||||||
Yes | 15.5 | 11.3 | 1218 | 14.0 | 17.3 | 12.6 | 2291 | 15.6 |
State Medical Assistance (AME)a | ||||||||
Yes | 0.9 | 1.4 | 93 | 1.1 | 2.1 | 1.9 | 298 | 2.0 |
Long-term disease status (LTD) for HCVb | ||||||||
Yes | 53.4 | 56.9 | 4276 | 54.6 | 43.2 | 48.9 | 6017 | 45.3 |
Previous HCV treatment initiation between 2007 and 2013 | ||||||||
No | 52.5 | 59.8 | 4786 | 55.0 | 72.1 | 74.9 | 10,703 | 73.1 |
Yesc | 47.5 | 40.2 | 3916 | 45.0 | 27.9 | 25.1 | 3947 | 26.9 |
with PEG-IFN/RBV bitherapy only | 72.5 | 72.1 | 2833 | 72.4 | 81.3 | 80.6 | 3200 | 81.1 |
with 1st-wave PIs only | 12.6 | 13.6 | 506 | 12.9 | 9.3 | 10.9 | 388 | 9.8 |
with PEG-IFN/RBV bitherapy and 1st-wave PIs | 14.9 | 14.3 | 575 | 14.7 | 9.4 | 8.5 | 359 | 9.1 |